当前位置： SCI文献检索 > CIRUGIA ESPANOLA期刊下所有文献 > [Variation in the prognostic value of p53 protein in relation to tumoral stage in patients with colorectal adenocarcinoma].

[Variation in the prognostic value of p53 protein in relation to tumoral stage in patients with colorectal adenocarcinoma].

Abstract：

OBJECTIVE:To analyze the prognostic value of p53 protein as a marker of recurrence risk in each tumoral stage. PATIENTS AND METHOD:A prospective study of a cohort of 288 patients who underwent surgery for colorectal adenocarcinoma was performed. Stage 1 of the tumor-node-metastasis (TNM) classification was found in 42 patients (14.6%), stage II in 144 (50%) and stage III in 102 (35.4%). Histopathological variables were examined in tumor samples fixed in formol and embedded in paraffin and p53 (DO7 antibody) and proliferative cell nuclear antigen (PC-10 antibody) proteins were determined using immunohistochemistry. The results of p53 were analyzed in each of the categories of clinical and histopathological variables. Recurrence-free survival was calculated using the Kaplan-Meier method. The value of each variable as a predictive marker for tumoral recurrence was analyzed using Cox regression analysis. Hazard ratios and 95% confidence intervals were calculated as indicators of relative risk. The analysis was applied to the whole cohort and was subsequently repeated in each TNM tumoral stage separately. RESULTS:Tumors with p53 protein overexpression more frequently recurred and showed lower recurrence-free survival at 5 years. However, the association between p53 expression and postoperative outcome was statistically significant in stage III tumors only. In this subgroup of patients, recurrence-free survival at 60 months was 60% in p53-negative tumors and was 26% in p53-positive tumors (p=0.010). In the multivariate analysis, p53 was an independent prognostic factor associated with a high risk of recurrence in stage III tumors (hazard ratio=2.76; 95% CI, 1.29-5.9; p=0.009). Overexpression of p53 showed prognostic value as a marker of high risk of recurrence in the form of metastases (hazard ratio=2.23; 95% CI, 1.04-4.75), but not as a prognostic marker of locoregional recurrence. No relationship was found between the state of p53 protein and the effect of postoperative adjuvant therapy. CONCLUSION:The p53 protein does not have the same prognostic value in all tumoral stages. This protein is only predictive of high recurrence risk in the subgroup of patients with stage III tumors.

journal_name

Cir Esp

journal_title

Cirugia espanola

authors

Díez M,Pollán M,Ramos P,Villeta R,Ratia T,Hernández P,Lozano O,Noguerales F,Granell J

doi

10.1016/s0009-739x(05)70840-x

subject

Has Abstract

pub_date

2005-04-01 00:00:00

pages

213-20

issue

eissn

0009-739X

issn

1578-147X

pii

13073290

journal_volume

pub_type

杂志文章

在线工具

[Variation in the prognostic value of p53 protein in relation to tumoral stage in patients with colorectal adenocarcinoma].